Clinical Trial Update: Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating obatoclax mesylate in combination with rituximab and bendamustine hydrochloride for relapsed or refractory non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Non-hodgkin Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Obatoclax Mesylate (obatoclax mesylate)
• Rituxan (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN